352 related articles for article (PubMed ID: 30385715)
1. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
2. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
3. UNC5293, a potent, orally available and highly MERTK-selective inhibitor.
Zheng H; Zhao J; Li B; Zhang W; Stashko MA; Minson KA; Huey MG; Zhou Y; Earp HS; Kireev D; Graham DK; DeRyckere D; Frye SV; Wang X
Eur J Med Chem; 2021 Aug; 220():113534. PubMed ID: 34038857
[TBL] [Abstract][Full Text] [Related]
4. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM; Page LS; Kirkpatrick GG; Eryildiz F; Montgomery SA; Zhang W; Wang X; Frye SV; Earp HS; Graham DK
Clin Cancer Res; 2017 Mar; 23(6):1481-1492. PubMed ID: 27649555
[No Abstract] [Full Text] [Related]
5. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
Summers RJ; Jain J; Vasileiadi E; Smith B; Chimenti ML; Yeung TY; Kelvin J; Wang X; Frye SV; Earp HS; Tyner JW; Dreaden EC; DeRyckere D; Graham DK
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551626
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
7. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.
Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
Pharmacol Ther; 2020 Sep; 213():107577. PubMed ID: 32417270
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
[TBL] [Abstract][Full Text] [Related]
10. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
11. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
[TBL] [Abstract][Full Text] [Related]
14. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
15. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
16. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota.
Dong M; Meng Z; Kuerban K; Qi F; Liu J; Wei Y; Wang Q; Jiang S; Feng M; Ye L
Cell Death Dis; 2018 Oct; 9(10):1039. PubMed ID: 30305604
[TBL] [Abstract][Full Text] [Related]
17. Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
19. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.
Kaplanov I; Carmi Y; Kornetsky R; Shemesh A; Shurin GV; Shurin MR; Dinarello CA; Voronov E; Apte RN
Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1361-1369. PubMed ID: 30545915
[TBL] [Abstract][Full Text] [Related]
20. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
